تحميل
NYSEHealthcareBiotechnology
أحدث البيانات المتاحة
12.08 US$
+0.15 US$ · +1.26%
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.
الإغلاق السابق
12.08 US$
+0.15 US$ · +1.26%
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.
نطاق اليوم
السعر الحالي 12.08 US$
نطاق 52 أسبوعًا
السعر الحالي 12.08 US$
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
نقاط GoAI
بيع
تقييم
27
مرتفع السعر
المشاعر
44
مختلط
المخاطر
68
مخاطر مرتفعة
الزخم
65
زخم متزايد
بحث كامل عن GoAI
تابع للاطلاع على أدلة ومحفزات ومخاطر أعمق.
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.
نطاق اليوم
السعر الحالي 12.08 US$
نطاق 52 أسبوعًا
السعر الحالي 12.08 US$
الدخل التشغيلي
صافي الدخل
| البند (USD) | السنة المالية 2025 | السنة المالية 2024 | السنة المالية 2023 | السنة المالية 2022 | السنة المالية 2021 |
|---|---|---|---|---|---|
| تكلفة البضاعة المباعة | 4.14 مليون USD | — | — | — | — |
| الربح الإجمالي | −4.14 مليون USD | — | — | — | — |
| البحث والتطوير | 635.07 مليون USD | 795.87 مليون USD | 373.28 مليون USD | 437.07 مليون USD | 181.49 مليون USD |
| مصاريف البيع والمصاريف العمومية والإدارية | 106.17 مليون USD | 89.24 مليون USD | 62.77 مليون USD | 130.86 مليون USD | 37.41 مليون USD |
| نفقات التشغيل | 741.24 مليون USD | 885.11 مليون USD | 436.05 مليون USD | 567.93 مليون USD | 218.9 مليون USD |
| دخل الفوائد | 14.59 مليون USD | 21.33 مليون USD | 17.73 مليون USD | — | — |
| الاستهلاك والإطفاء | 9.92 مليون USD | 7.86 مليون USD | 6.91 مليون USD | 1.39 مليون USD | 1.39 مليون USD |
| الدخل التشغيلي | −745.38 مليون USD | −885.11 مليون USD | −436.05 مليون USD | −567.93 مليون USD | −218.9 مليون USD |
| صافي الدخل | −738.82 مليون USD | −846.42 مليون USD | −408.17 مليون USD | −570.28 مليون USD | −213.8 مليون USD |
تم تحديث حقائق الشركة 11 أكتوبر 2026.
أحدث النتائج المعلنة
أحدث النتائج المعلنة
قد تتغير تقديرات المحللين الخارجيين، وهي ليست توصيات من GoAI.
متوسط الهدف
20.00 US$
ارتفاع محتمل بنسبة 65.56%صناديق متداولة تفصح عن تعرضها لهذا السهم.
State Street SPDR S&P Biotech ETFXBI44.73 مليون0.45%9.87 مليار USD0.35%153.77 US$+3.00%
iShares Russell 2000 ETFIWM41.91 مليون0.05%78.74 مليار USD0.19%278.94 US$+0.49%
Vanguard Extended Market ETFVXF22.98 مليون0.02%95.4 مليار USD0.05%235 US$+0.80%
iShares Russell 2000 Growth ETFIWO14.7 مليون0.11%13.92 مليار USD0.24%356.78 US$+0.94%
iShares Biotechnology ETFIBB11.88 مليون0.11%10.82 مليار USD0.44%206.49 US$+3.00%
Vanguard Russell 2000 ETFVTWO11.71 مليون0.06%18 مليار USD0.06%112.66 US$+0.50%
Schwab U.S. Small-Cap ETFSCHA7.84 مليون0.04%21.82 مليار USD0.03%32.79 US$+0.40%
Simplify Health Care ETFPINK6.1 مليون1.91%319.15 مليون USD0.51%38.527 US$+2.57%State Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHASimplify Health Care ETFPINKالمحتوى المُنشأ بالذكاء الاصطناعي وبيانات السوق المتأخرة لأغراض معلوماتية وتعليمية فقط، ولا تُعد نصيحة استثمارية.
